Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. MASH is the updated term for ...

Madrigal Pharma was the first drugmaker to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, and has now signed a major alliance with China's Ribo Life Science ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

View post: Why Reviewers Say These $50 Adjustable Dumbbells Are Better Than $400 Luxury Models View post: Dr. Martens' Rugged Waxed 1460 Boots That Get Better-Looking Over Time Are $85 Off Right Now ...

MASLD/MASH represents a growing clinical and economic burden, with MASH conferring heightened risks of advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related mortality. Noninvasive ...